Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

A Randomized, Open-label, Multi-center Phase III Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301 in Postoperative Patients Requiring Central Parenteral Nutrition

ID
Name
IN_CPN_301
Description
This study is designed to evaluate the safety and efficacy of IN-C006 inj. and RCN301 in postoperative patients requiring central parenteral nutrition.
Trial arms
Trial start
2022-05-04
Estimated PCD
2022-12-09
Trial end
2022-12-15
Status
Completed
Phase
Early phase I
Treatment
IN-C006 inj.
IN-C006 will be injected continuously for 3 days.
Arms:
IN-C006 inj.
Other names:
IN-C006 inj
RCN301
RCN301 will be injected continuously for 3 days.
Arms:
RCN301
Size
60
Primary endpoint
Adverse drug reaction rate
Day 1 to Day 4
Eligibility criteria
Inclusion Criteria: * Age over 19 at the time of obtaining the informed consent form * Requiring over 3 days of parenteral nutrition via a central vein after an operation * BMI 16 \~ 30 kg/㎡ Exclusion Criteria: * Has received parenteral nutrition within 7 days of screening * Severe dyslipidemia * Uncontrolled diabetes * Clinically significant liver disease * Clinically significant kidney disease
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ACTUAL'}}
Updated at
2023-09-28

1 organization

2 products

1 indication

Organization
HK inno.N Corporation
Product
IN-C006
Indication
Parenteral nutrition
Product
RCN301